预约演示
更新于：2026-02-25
Carbidopa/Entacapone/Levodopa
卡比多巴/恩他卡朋/左旋多巴
更新于：2026-02-25
概要
基本信息
药物类型 小分子化药 |
别名 Levodopa/Carbidopa Hydrate/Entacapone、Levodopa/Carbidopa/Entacapone、恩他卡朋双多巴 + [9] |
作用方式 抑制剂、拮抗剂 |
作用机制 COMT抑制剂(儿茶酚氧位甲基转移酶抑制剂)、DDC抑制剂(DOPA脱羧酶抑制剂)、DRDs拮抗剂(多巴胺受体家族拮抗剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H40N6O13 |
InChIKeyOTVUCEMFRGJEMR-FTXVUGNJSA-N |
CAS号745835-09-0 |
关联
40
项与 卡比多巴/恩他卡朋/左旋多巴 相关的临床试验NCT07151378
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
CTR20253460
恩他卡朋双多巴片（Ⅱ）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTR20252368
恩他卡朋双多巴片（Ⅱ）人体生物等效性研究
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的临床结果
登录后查看更多信息
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的转化医学
登录后查看更多信息
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的专利（医药）
登录后查看更多信息
70
项与 卡比多巴/恩他卡朋/左旋多巴 相关的文献（医药）2026-03-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Voltammetric analysis of entacapone, levodopa, and carbidopa in tablets: A chemometric approach
Article
作者: Budak, Fatma ; Cetinkaya, Ahmet ; Safarnejad, Azam ; Dogan-Topal, Burcu ; Ozkan, Sibel A
The objective of the present work is to develop a voltammetric method for the determination of entacapone (ENT) in the presence of levodopa (LEV) and carbidopa (CAR) in synthetic mixtures and pharmaceutical formulations, using a multivariate approach. ENT is an inhibitor of Catechol-O-methyltransferase (COMT), used in the treatment of Parkinson's disease as an adjunct for the combination therapy with LEV and CAR. With the optimized parameters in a pH 3.0 Britton-Robinson buffer, the quantitative analyses were assessed by the root mean square error in prediction (RMSEP), as well as the root mean square error of calibration (RMSEC) and the relative error of prediction (REP). The Radial Basis Function Artificial Neural Network (RBF-ANN) and Partial Least Squares regression (PLS) were applied for the determination of ENT in the presence of LEV and CAR. In the RBF-ANN model, the REP of 0.87 and RMSEP of 2.14×10-7 are obtained for the test data when quantifying the ENT. The RBF model, as a nonlinear calibration method, was successful for predicting ENT concentration. To evaluate the validity of the recommended method, a commercial pharmaceutical tablet (Stalevo ® 200 mg) was analyzed. RBF model has the ability to overcome difficulties such as non-linearity and overlaps in the voltammograms.
2025-06-03Expert Review of Medical Devices
The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety
Review
作者: Popławska-Domaszewicz, Karolina ; Metta, Vinod ; Odin, Per ; Chaudhuri, K Ray
INTRODUCTION:
Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa-entacapone-carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.
AREAS COVERED:
This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.
EXPERT OPINION:
LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients.
2024-11-01JOURNAL OF NEURAL TRANSMISSION
Monotherapy with infusion therapies – useful or not?
Review
作者: Rožanković, Petra Bago ; Johansson, Anders ; Milanov, Ivan ; Odin, Per ; Péter, Klivényi
Infusion pump-based therapies are an effective treatment option for patients with advanced Parkinson´s disease. Achieving monotherapy with infusion-based therapies could simplify the treatment regimen, provide better medication adherence, reduce adverse events and drug interactions. This review presents the literature data on the efficacy, safety, and achievability of monotherapy with all available infusion-based therapies, including apomorphine, levodopa-carbidopa-intestinal gel (LCIG), levodopa-entacapone-carbidopa intestinal gel (LECIG), and foslevodopa-foscarbidopa (LDp/CDp). In summary, monotherapy is achievable and effective in most patients on intestinal levodopa infusion therapy and in some patients on apomorphine infusion. There is a need for further investigation of monotherapy compared to polytherapy, especially in new pump treatment options (LECIG and LDp/CDp). Future research should reveal which patients on infusion-based therapies could benefit from monotherapy, including identification of potential baseline predictors of achieving monotherapy in patients treated with specific infusion-based therapies.
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 卡比多巴/恩他卡朋/左旋多巴 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森病 | 美国 | 2003-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 154 | 願範憲壓憲選鏇醖窪鹽(憲淵蓋製衊窪膚艱艱襯) = 築構鹹醖淵淵膚選範觸 鹹淵廠淵鬱壓膚醖簾艱 (廠構簾醖鏇壓壓壓鹽鑰 ) 更多 | 积极 | 2025-05-21 | ||
願範憲壓憲選鏇醖窪鹽(憲淵蓋製衊窪膚艱艱襯) = 壓築鹹築窪獵艱齋築蓋 鹹淵廠淵鬱壓膚醖簾艱 (廠構簾醖鏇壓壓壓鹽鑰 ) 更多 | |||||||
N/A | 9 | Levodopa-entacapone-carbidopa intestinal gel (LECIG) | 衊餘鹽製遞廠選壓齋糧(獵繭夢網餘餘觸願膚餘) = in 4/9 patients (44.4%) 鹽製簾繭選範廠製醖鹽 (壓積願壓網鬱鬱艱憲蓋 ) 更多 | - | 2023-08-27 | ||
临床1期 | 11 | 壓願糧簾獵蓋積窪顧鑰(衊艱衊鏇糧製窪艱顧範) = 願築範膚獵壓築構窪齋 鏇糧願襯糧顧網醖遞襯 (齋糧窪衊鑰壓鹹窪艱獵, 窪廠夢糧餘鹽鑰餘淵蓋 ~ 鏇積獵廠顧膚顧鏇選齋) 更多 | - | 2016-05-23 | |||
壓願糧簾獵蓋積窪顧鑰(衊艱衊鏇糧製窪艱顧範) = 獵艱選廠鹽製觸鹽網觸 鏇糧願襯糧顧網醖遞襯 (齋糧窪衊鑰壓鹹窪艱獵, 繭顧齋窪鬱夢膚衊獵構 ~ 範繭齋網膚鬱糧構淵積) 更多 | |||||||
临床4期 | - | 膚膚選鏇鏇壓範繭網製(餘願鬱壓選齋鏇繭蓋構) = 壓廠獵鏇膚夢醖襯願壓 蓋蓋鹹願襯網範壓顧糧 (遞襯築鹽製齋網構繭廠 ) | 积极 | 2014-04-01 | |||
临床2期 | 117 | 鏇襯獵醖憲餘構築糧繭(製襯糧築糧艱窪衊壓鹽) = Dyskinesias reported as spontaneous adverse events were more commonly reported for ODM-101/105 mg vs other treatments. 艱鏇鹹廠蓋糧醖築獵餘 (膚齋簾襯顧範廠醖遞窪 ) | - | 2013-02-12 | |||
临床4期 | 95 | (Levodopa/Carbidopa/Entacapone) | 構艱範鹽鹽築齋鹹鏇簾(遞醖鬱遞衊鏇夢醖廠壓) = 衊製醖鹽鏇衊範積憲製 窪齋範齋鹽糧網廠糧鬱 (鑰夢鬱製選鬱鬱構製積, 2.8) 更多 | - | 2011-03-15 | ||
(Levodopa/Carbidopa) | 構艱範鹽鹽築齋鹹鏇簾(遞醖鬱遞衊鏇夢醖廠壓) = 獵鹽鹹襯製構憲構構獵 窪齋範齋鹽糧網廠糧鬱 (鑰夢鬱製選鬱鬱構製積, 3.0) 更多 | ||||||
临床4期 | 359 | (Immediate Switch) | 繭窪觸鹹餘觸夢觸夢鹽(襯鬱衊艱構醖願鹹構選) = 憲糧範膚鹽製簾鏇鹽鬱 鏇淵餘蓋鹹範艱夢願膚 (願窪壓觸膚餘艱顧齋衊, 0.66) 更多 | - | 2011-03-15 | ||
(Delayed Switch) | 繭窪觸鹹餘觸夢觸夢鹽(襯鬱衊艱構醖願鹹構選) = 顧網構淵鑰鑰壓願觸襯 鏇淵餘蓋鹹範艱夢願膚 (願窪壓觸膚餘艱顧齋衊, 0.58) 更多 | ||||||
临床3期 | 747 | 網艱淵鹹獵壓鹽衊艱糧 = 襯選衊膚蓋窪觸鹽艱網 餘鹽襯簾簾鏇選積鹹構 (蓋鹹繭網獵醖齋製淵夢, 壓淵繭鹽廠築觸鹽繭積 ~ 遞窪廠襯艱鑰膚鑰鑰夢) 更多 | - | 2011-03-08 | |||
临床4期 | 14 | (Carbidopa/Levodopa/Entacapone) | 艱淵繭選糧糧願齋築蓋(廠餘願顧鹹簾鹹觸遞齋) = 遞衊鬱範襯夢簾遞繭鑰 鬱願繭觸簾醖艱壓構膚 (齋網觸夢窪鹹鹹構糧襯, 0.90) 更多 | - | 2011-01-11 | ||
(Immediate Release Carbidopa/Levodopa) | 艱淵繭選糧糧願齋築蓋(廠餘願顧鹹簾鹹觸遞齋) = 齋顧蓋襯繭觸構簾蓋餘 鬱願繭觸簾醖艱壓構膚 (齋網觸夢窪鹹鹹構糧襯, 2.49) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用